Kliniken Essen-Mitte

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto (2018) Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching P, Lederer B, et al. Journal article Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf (R)) in patients with metastatic colorectal cancer (CRC) in clinical-routine use (2018) Cao J, Wiesweg M, Fuchs M, Stein A, Karthaus M, Lettmaier S, Kretzschmar A, et al. Conference contribution Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany (2018) Lux MP, Nabieva N, Hildebrandt T, Rebscher H, Kummel S, Blohmer JU, Schrauder MG Journal article rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology (2018) Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G, Fasching P, Beckmann M, Ekici AB, et al. Journal article Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor (2018) Loibl S, Weber K, Huober J, Krappmann K, Marme F, Schem C, Engels K, et al. Journal article Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy (2018) Denkert C, Von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, et al. Journal article Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study (2017) Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching P, Campone M, et al. Journal article No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival (2017) Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, et al. Journal article Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2017) Kuemmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, et al. Journal article Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) (2017) Loibl S, De La Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, et al. Journal article